ArticleFrontiers in oncology2026
Case Report: Management challenges of active tuberculosis complicated by thrombocytosis and squamous cell lung carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This report assesses the feasibility of a sequential treatment strategy for a patient with active tuberculosis (TB) complicated by thrombocytosis and squamous cell lung carcinoma, involving initial anti-TB therapy combined with aspirin, followed by anticancer treatment. It highlights the challenge of balancing infection control, hematologic stability, and oncologic management in this complex scenario. Case presentation: A 55-year-old man with a 15-day history of cough, sputum, and fever was found to have markedly elevated platelet levels. Bronchoscopy confirmed active TB with concurrent lung cancer. Following anti-TB therapy combined with aspirin for antiplatelet management, platelet counts returned to normal. One month later, antitumor chemotherapy with nab-paclitaxel and carboplatin was initiated, leading to effective disease control. Conclusion: Active TB complicated by thrombocytosis and squamous cell lung carcinoma poses diagnostic and therapeutic challenges. This case demonstrates that early anti-TB therapy combined with aspirin can effectively normalize platelet counts and facilitate the timely initiation of anticancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.